The Latin America, Middle East and Africa Transcriptomics Market is expected to witness market growth of 11.7% CAGR during the forecast period (2021 2027).
The transcriptomics market is relatively a new industry with a lot of room for expansion. Recent technological developments have facilitated the quick adoption of technology. Transcriptomics enables the isolation of a single cell with specified traits from a heterogeneous mixture, as well as gene and protein expression analyses. Transcriptomics technology's unique ability to incorporate data from diverse substances and cells to examine cell-to-cell differentiation allows researchers to investigate mechanisms that are observable at the transcriptome level.
Evaluating the expression of an organism's genes in various tissues or environments, or at different periods, exposes characteristics of an organism's biology and how genes are regulated. It can also be utilized to infer the roles of genes that have yet to be annotated. Transcriptome analysis has aided in the knowledge of human disease by allowing researchers to investigate how gene expression changes in various organisms. Gene expression analysis in its whole allows for the observation of broad coordinated patterns that are impossible to detect with more specialized assays.
Some of the key trends of the Transcriptomics Market are an expansion in the number of biopharmaceutical companies, academic institutions, and research institutes, as well as significant investments in biomarker development and cancer research.
Given the vast regions covered by developed-world developments in molecular and omics-based technologies, their adoption and implementation in developed countries remain dubious. Ageing and population expansion, as well as increased incidence of risk factors, have made cancer a pervasive problem in African countries. In 2008, Africa had 715,000 new cancer cases and 542,000 fatalities, according to estimates. According to United Nations population predictions, Africa's population is expected to grow by 60% overall between 2010 and 2030, and by 90% for those aged 60 and more, the age at which cancer is most common. Despite this growing burden, cancer continues to be a low priority for public health throughout Africa, with a few exceptions.
The Brazil market dominated the LAMEA Transcriptomics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $142.8 million by 2027. The Argentina market is estimated to grow at a CAGR of 12.3% during (2021 - 2027). Additionally, The UAE market is expected to witness a CAGR of 11.4% during (2021 - 2027).
Based on Technology, the market is segmented into q PCR, Microarrays, and Sequencing Technology. Based on Application, the market is segmented into Drug Discovery, Diagnostics & Disease Profiling, and Others. Based on Component, the market is segmented into Consumables, Instruments, Software, and Services. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fluidigm Corporation, Promega Corporation, General Electric (GE) Co., Merck & Co., Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., and Qiagen N.V.
The transcriptomics market is relatively a new industry with a lot of room for expansion. Recent technological developments have facilitated the quick adoption of technology. Transcriptomics enables the isolation of a single cell with specified traits from a heterogeneous mixture, as well as gene and protein expression analyses. Transcriptomics technology's unique ability to incorporate data from diverse substances and cells to examine cell-to-cell differentiation allows researchers to investigate mechanisms that are observable at the transcriptome level.
Evaluating the expression of an organism's genes in various tissues or environments, or at different periods, exposes characteristics of an organism's biology and how genes are regulated. It can also be utilized to infer the roles of genes that have yet to be annotated. Transcriptome analysis has aided in the knowledge of human disease by allowing researchers to investigate how gene expression changes in various organisms. Gene expression analysis in its whole allows for the observation of broad coordinated patterns that are impossible to detect with more specialized assays.
Some of the key trends of the Transcriptomics Market are an expansion in the number of biopharmaceutical companies, academic institutions, and research institutes, as well as significant investments in biomarker development and cancer research.
Given the vast regions covered by developed-world developments in molecular and omics-based technologies, their adoption and implementation in developed countries remain dubious. Ageing and population expansion, as well as increased incidence of risk factors, have made cancer a pervasive problem in African countries. In 2008, Africa had 715,000 new cancer cases and 542,000 fatalities, according to estimates. According to United Nations population predictions, Africa's population is expected to grow by 60% overall between 2010 and 2030, and by 90% for those aged 60 and more, the age at which cancer is most common. Despite this growing burden, cancer continues to be a low priority for public health throughout Africa, with a few exceptions.
The Brazil market dominated the LAMEA Transcriptomics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $142.8 million by 2027. The Argentina market is estimated to grow at a CAGR of 12.3% during (2021 - 2027). Additionally, The UAE market is expected to witness a CAGR of 11.4% during (2021 - 2027).
Based on Technology, the market is segmented into q PCR, Microarrays, and Sequencing Technology. Based on Application, the market is segmented into Drug Discovery, Diagnostics & Disease Profiling, and Others. Based on Component, the market is segmented into Consumables, Instruments, Software, and Services. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fluidigm Corporation, Promega Corporation, General Electric (GE) Co., Merck & Co., Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., and Qiagen N.V.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- q PCR
- Microarrays
- Sequencing Technology
By Application
- Drug Discovery
- Diagnostics & Disease Profiling
- Others
By Component
- Consumables
- Instruments
- Software
- Services
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Fluidigm Corporation
- Promega Corporation
- General Electric (GE) Co.
- Merck & Co., Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Qiagen N.V.
Unique Offerings from the publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Transcriptomics Market by Technology
Chapter 5. LAMEA Transcriptomics Market by Application
Chapter 6. LAMEA Transcriptomics Market by Component
Chapter 7. LAMEA Transcriptomics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Fluidigm Corporation
- Promega Corporation
- General Electric (GE) Co.
- Merck & Co., Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Qiagen N.V.
Methodology
LOADING...
